#United States #Washington #Vanda Pharmaceuticals #Hetlioz #DSWPD

Vanda Pharmaceuticals Unveils Promising Results for HETLIOZ® in Phase III Trials

Vanda Pharmaceuticals Inc. has recently released compelling topline data from a crucial Phase III clinical trial for its drug HETLIOZ® (tasimelteon) aimed at treating Delayed Sleep-Wake Phase Disorder (DSWPD). The findings highlight the efficacy of HETLIOZ®, effectively positioning it as a potential first-of-its-kind FDA-approved medication for this condition.

Study Overview

The pivotal trial involves a multicenter, double-blind, randomized, placebo-controlled design that enrolled over 260 adult participants aged between 18 to 75 years suffering from DSWPD. Conducted across 26 clinical sites in the U.S. and Europe, the study was structured to assess the impact of administering a daily dose of 20 mg tasimelteon over 28 days. The primary endpoint of this study was to gauge the change in sleep onset timing—a critical measure for those affected by this disorder.

Significant Findings

Impressively, the results indicated that HETLIOZ® produced a mean shift of 42.5 minutes regarding sleep onset timing in participants. In contrast, those taking a placebo only saw a slight 5.4-minute shift, leading to a significant 37.1-minute difference (p=0.022) that supports the effectiveness of the drug. Furthermore, an exploratory responder analysis revealed that 60% of participants on HETLIOZ® managed to advance their sleep timing by at least 30 minutes, in stark contrast to the mere 15% in the placebo group.

```markdown
```

These results are critical, as they not only demonstrate the drug's efficacy but also support Vanda Pharmaceuticals' plans for submitting a supplemental New Drug Application (sNDA) to the FDA, advocating for the approval of HETLIOZ® specifically for DSWPD.

Understanding Delayed Sleep-Wake Phase Disorder

DSWPD is characterized by a significant misalignment of an individual’s internal circadian rhythms, leading to extreme difficulty in maintaining conventional sleep-wake patterns. This condition goes beyond the typical “night owl” behavior; rather, it reflects a stable clock-setting that predisposes individuals to late sleep onset, often exacerbating issues related to daily functioning. Experts estimate that the disorder affects around 0.2% to 1.5% of adults in the United States, which translates to approximately 0.5 to 4.1 million individuals. Such prevalence underscores the need for effective and approved treatment options.

Vanda's Commitment to Sleep Disorders

HETLIOZ® was originally approved by the FDA in 2014 for the treatment of Non-24-Hour Sleep-Wake Disorder and further indicated for nighttime disturbances in those with Smith-Magenis Syndrome in 2020. By extending its use to include DSWPD, Vanda aims to address a considerable unmet medical need in the realm of circadian rhythm sleep disorders.

Dr. Mihael H. Polymeropoulos, President and CEO of Vanda Pharmaceuticals, emphasized the implications of the study by saying, "People with DSWPD often remain undiagnosed and undertreated, especially due to the lack of approved treatment options. This study enhances our understanding of the versatile capabilities of HETLIOZ®. We are eager to work with the FDA on this front and hope to pave the way towards making HETLIOZ® an approved treatment for DSWPD."

Conclusion

As Vanda Pharmaceuticals moves towards filing its sNDA, the encouraging results from this Phase III trial signal a potentially significant advancement in therapeutic options for individuals with Delayed Sleep-Wake Phase Disorder. With this innovative approach to managing sleep disorders, HETLIOZ® could soon become a beacon of hope for millions seeking a resolution to their sleep-related challenges.